Success Metrics

Clinical Success Rate

100.0%

Based on 5 completed trials

Completion Rate

100%(5/5)

Active Trials

0(0%)

Results Posted

20%(1 trials)

Phase Distribution

Ph phase_1

80%

Ph phase_4

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

4(80.0%)

Phase 4Post-market surveillance

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 14 (80.0%)

Phase 41 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_1

Clinical Trials (5)

Showing 5 of 5 trials

NCT03733574Phase 1

A Study of LY03005 vs Pristiq

Completed

NCT03357796Phase 1

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

Completed

NCT02988024Phase 1

Pilot BA Study of New LY03005 vs Pristiq

Completed

NCT01316302Phase 4

12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder

Completed

NCT02055300Phase 1

Safety, Tolerability and Pharmacokinetics Study of LY03005

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5